New clinical data push: Thermo Fisher’s PPD CorEvitas Chronic Hand Eczema Registry targets real-world gaps

Thermo Fisher is expanding its clinical evidence footprint with the PPD CorEvitas Chronic Hand Eczema Registry, designed to collect regulatory-grade real-world data across North America on a hard-to-treat skin disease.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 7:53 AM ET. Details in the imprint.

Thermo Fisher Scientific is pushing deeper into real-world dermatology data with its newly launched PPD CorEvitas Chronic Hand Eczema Registry, a prospective observational cohort initiative focused on chronic hand eczema patients in North America. The registry is designed to generate regulatory-grade evidence on disease burden, treatment patterns and outcomes in routine clinical practice, addressing a long-standing data gap for this often debilitating condition. Thermo Fisher and CorEvitas highlighted that the program is already open to enrollment across North America.

What Thermo Fisher’s chronic hand eczema registry does and how it is structured

The PPD CorEvitas Chronic Hand Eczema Registry is set up as a prospective, observational cohort, meaning participating patients are followed over time without the constraints of a randomized clinical trial, while their real-world treatment journeys and outcomes are systematically documented. Chronic hand eczema is a heterogeneous disease with multiple subtypes and triggers, and the registry aims to capture detailed clinical phenotyping, quality-of-life measures and safety data that are typically underreported outside academic trials according to the launch communication and supporting materials. In addition to physician-reported information, the structure is expected to include patient-reported outcomes to provide regulators and payers with a more complete picture of therapy effectiveness in everyday practice.

Unlike short-term interventional trials that focus on a specific product, the registry is treatment-agnostic and is designed to record data across topical therapies, systemic immunomodulators and newer biologic and JAK inhibitor options, providing a neutral platform to compare real-world performance. Thermo Fisher’s PPD clinical research business brings operational experience from large-scale registries in immunology and dermatology, while CorEvitas contributes its established infrastructure for longitudinal observational studies. The combination is significant for sponsors who need high-quality evidence to support label expansions, post-marketing safety commitments and health-technology assessment submissions in a disease that crosses dermatology, occupational medicine and allergy segments.

Geographically, the registry is being rolled out across sites in the United States and Canada, targeting both academic centers and community dermatology practices to capture a broad spectrum of disease severity and practice patterns. Chronic hand eczema often affects working-age adults in manual occupations, making long-term functional outcomes and work productivity loss key data points for employers and insurers. By standardizing data capture tools and definitions across participating sites, Thermo Fisher and CorEvitas aim to reduce variability and create a dataset that can withstand scrutiny from regulators such as the US Food and Drug Administration and other authorities when used to support labeling or risk-management initiatives. The initiative also positions the company as an evidence-generation partner for drug developers active in atopic dermatitis and related inflammatory skin diseases.

From an operational standpoint, electronic case report forms and centralized data management are expected to streamline participation for sites and reduce the burden on clinicians compared with traditional paper-based registries. Governance structures typically include scientific steering committees composed of dermatologists and methodologists who oversee protocol amendments, endpoint definitions and publication strategy, ensuring that the data generated translate into peer-reviewed outputs that can influence guidelines and reimbursement decisions. The registry’s focus on regulatory-grade data implies rigorous monitoring, data validation and traceability processes, all of which align with expectations for submissions involving real-world evidence.

For Thermo Fisher, expanding the CorEvitas portfolio into chronic hand eczema complements existing registries in rheumatology and other immune-mediated conditions, reinforcing its positioning as a partner across the full evidence lifecycle, from early-phase trials to post-authorization studies. The company’s official materials present the chronic hand eczema initiative as part of a broader strategy to support life science customers with data, analytics and laboratory services, leveraging PPD’s contract research capabilities alongside CorEvitas’ observational expertise. Thermo Fisher’s corporate information emphasizes that real-world data services have become a growing part of its clinical research offering, reflecting rising demand from biopharma clients.

Within Thermo Fisher’s diversified portfolio, which spans analytical instruments, reagents, consumables and contract services, the PPD CorEvitas registries form part of the Laboratory Products and Biopharma Services segment that serves pharmaceutical and biotech customers rather than end-consumers. These kinds of observational platforms do not contribute revenue on the scale of core instrument franchises, but they are strategically important for deepening relationships with sponsors developing dermatology therapies and for enabling follow-on projects such as sub-studies, biomarker analyses and method development. For equity investors, the launch underlines Thermo Fisher’s continued push into service-based revenue streams that are less cyclical than capital equipment sales. Shares of Thermo Fisher Scientific (US8835561023) traded on the NYSE at $473.08 at the close on 06/15/2026, with market data provided by MarketBeat and other financial information services. According to MarketBeat, the company’s shares have recently traded in the mid-$470s range.

PPD CorEvitas Chronic Hand Eczema Registry in brief

• Product: PPD CorEvitas Chronic Hand Eczema Registry
• Manufacturer: Thermo Fisher Scientific Inc.
• Category: New Release / Clinical Registry Service
• Launch date: 06/2026 (North America)
• MSRP / Price: Not publicly disclosed (sponsor-specific service pricing)
• Availability: Open to enrollment at participating clinical sites in North America
• Target audience: Biopharmaceutical sponsors, clinical researchers, dermatology and immunology stakeholders
• Key differentiator / USP: Prospective, regulatory-grade real-world evidence platform dedicated to chronic hand eczema in routine practice settings

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.